Published in J Transl Med on May 18, 2004
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2009) 2.55
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Translational education: tools for implementing the CanMEDS competencies in Canadian urology residency training. Can Urol Assoc J (2008) 1.60
Incorporating collaboratory concepts into informatics in support of translational interdisciplinary biomedical research. Int J Med Inform (2008) 1.49
Close to the bench as well as at the bedside: involving service users in all phases of translational research. Health Expect (2011) 1.34
The advancement of translational medicine-from regional challenges to global solutions. Nat Med (2009) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Unraveling the autoimmune translational research process layer by layer. Nat Med (2012) 1.27
Knowledge transfer & exchange through social networks: building foundations for a community of practice within tobacco control. Implement Sci (2006) 1.23
The translational research impact scale: development, construct validity, and reliability testing. Eval Health Prof (2013) 1.15
Network structure and the role of key players in a translational cancer research network: a study protocol. BMJ Open (2012) 1.08
A decade plus of translation: what do we understand? Clin Transl Med (2012) 1.04
Conflicts of interest in translational research. J Transl Med (2004) 1.03
Implementations of translational medicine. J Transl Med (2005) 1.01
Translational Medicine is developing in China: a new venue for collaboration. J Transl Med (2011) 0.95
Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles. J Transl Med (2009) 0.93
Collaborative software for traditional and translational research. Hum Genomics (2012) 0.91
Translational researches require effective protocols for knowledge and technology transfer and integration. Bioimpacts (2011) 0.89
Leadership in complex networks: the importance of network position and strategic action in a translational cancer research network. Implement Sci (2013) 0.84
Understanding the response to immunotherapy in humans. Springer Semin Immunopathol (2005) 0.83
AAAS joins the Translational Medicine family. J Transl Med (2009) 0.82
New take on comparative immunology: relevance to immunotherapy. Immunotherapy (2009) 0.82
The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J Transl Med (2008) 0.81
Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med (2004) 0.80
Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576. Psychopharmacology (Berl) (2011) 0.80
Managing Expectational Language: Translational genetic professionals consider the clinical potential of next-generation sequencing technologies. New Genet Soc (2014) 0.78
Translational research in atrial fibrillation: a quest for mechanistically based diagnosis and therapy. Circ Arrhythm Electrophysiol (2012) 0.78
Standardizing in vitro diagnostics tasks in clinical trials: a call for action. Ann Transl Med (2016) 0.77
The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward. J Transl Med (2008) 0.75
A road map to Translational Medicine in Qatar and a model for the world. J Transl Med (2012) 0.75
Turning laboratory findings into therapy: a marathon goal that has to be reached. Pol Arch Med Wewn (2009) 0.75
The determinants of translational medicine success - a managerial contribution. Transl Med UniSa (2013) 0.75
Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets. Biomedicines (2016) 0.75
Central challenges facing the national clinical research enterprise. JAMA (2003) 17.41
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Translational Medicine: A two-way road. J Transl Med (2003) 3.50
Materializing research promises: opportunities, priorities and conflicts in translational medicine. J Transl Med (2004) 2.00
Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol (2001) 1.52
Clinician scientist training program: a proposal for training medical students in clinical research. J Investig Med (2001) 1.52
Why we're losing the war on cancer (and how to win it). Fortune (2004) 1.43
Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling. J Transl Med (2003) 1.28
Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. J Appl Physiol (1985) (2003) 1.25
Breaking down the walls: thoughts on the scholarship of integration. Acad Med (2000) 1.18
New trends in bioinformatics: from genome sequence to personalized medicine. Exp Gerontol (2003) 1.15
National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation (2004) 1.07
Translational medicine in the first year: integrative cores. Acad Med (2002) 1.06
Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation (2003) 1.02
Clinical faculty tracks and academic success at the University of California Medical Schools. Acad Med (2004) 1.02
Translational ethics: a perspective for the new millennium. Arch Surg (2000) 0.97
Recommendations for the future of translational radiobiology research: a Canadian perspective. Radiother Oncol (2004) 0.88
Impact of molecular medicine on pathophysiology, medical practice, and medical education. Croat Med J (2003) 0.88
Providing research and research training infrastructures for clinical research in the reproductive sciences. Am J Obstet Gynecol (2002) 0.87
American Society for Clinical Oncology 39th Annual Meeting, Chicago, Illinois, USA, 31 May to 3 June 2003: breast cancer neoadjuvant and adjuvant chemotherapy--prognostic and predictive markers. Breast Cancer Res (2003) 0.83
The relationship between surgeon and basic scientist. Transpl Immunol (2002) 0.83
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science (2007) 4.60
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol (2006) 3.20
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol (2008) 2.72
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 2.70
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Immune-driven recombination and loss of control after HIV superinfection. J Exp Med (2008) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol (2007) 2.26
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol (2004) 2.21
Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med (2003) 2.17
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol (2008) 2.14
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One (2008) 2.06
De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 2.04
A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol (2012) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods (2006) 1.99
Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol (2006) 1.99
Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol (2006) 1.98
Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol (2010) 1.97
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood (2006) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
What's next in translational medicine? Clin Sci (Lond) (2007) 1.85
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol (2005) 1.76
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74
Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods (2003) 1.73
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
The dual role of IL-10. Trends Immunol (2003) 1.72
Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol (2006) 1.69
Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol (2004) 1.68
Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics (2011) 1.68
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. AIDS (2008) 1.67
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res (2006) 1.65
Monoclonal antibodies for cancer immunotherapy. Lancet (2009) 1.64
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
The immunologic constant of rejection. Trends Immunol (2008) 1.62
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Obstacles and opportunities in translational research. Nat Med (2005) 1.59
Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses. J Infect Dis (2005) 1.58